摘要
目的:观察吉西他滨单药及联合顺铂在老年晚期非小细胞肺癌的临床疗效及不良反应。方法:76例晚期老年非小细胞肺癌随机分为两组,吉西他滨联合顺铂组(GP)36例,吉西他滨单药组(G)40例。结果:GP组总有效率为36.1%,中位生存期(MST)为9.2个月,疾病缓解时间(DRT)为4.0个月;单药(G)组分别为30.0%,8.6个月及4.3个月,两组间差异无统计学意义(P>0.05)。在生存质量改善方面,GP组一般状况KPS评分增加3例、稳定14例,G组增加11例、稳定24例,两组间差异无统计学意义(P>0.05);GP组体重增加7例、稳定13例,G组增加15例、稳定21例,两组间差异有统计学意义(P<0.05)。最常见的不良反应为骨髓抑制,主要表现为白细胞及血小板下降,GP组和G组Ⅲ度～Ⅳ度反应发生率分别为11.1%、7.5%,2.7%、5.0%,差异无统计学意义(P>0.05);GP组发生Ⅲ度～Ⅳ度恶心呕吐反应19例,占52.7%,明显高于单药G组(P<0.05),其余不良反应轻微,可耐受。结论:吉西他滨单药与吉西他滨联合顺铂治疗老年晚期非小细胞肺癌疗效相似,但不良反应轻,有助于提高生活质量,吉西他滨单药化疗更适合于老年晚期非小细胞肺癌的治疗。
Objective： To evaluate the effects and safety of gemcitabine single-agent and gemcitabine plus cisplatin regimen for elder patients with advanced non-small cell lung cancer. Methods： 76 cases of eider patients with advanced non-small cell lung cancer were randomly divided into the gemcitabine plus cisplatin regimen group （GP） and the gemcitabine regimen group（G）. There were 36 patients in the GP group, and 40 patients in the G group. Results： The response rates of GP and G group were 36.1% and 30.0% respectively. The median survival time （MST） of GP and G group were 9.2 months and 8.6 months respectively, and the disease remission time （DRT） were 4.0 months and 4.3 months respectively. There were no significant difference （ P 〉 0.05 ） in two groups. With regard to the improvement of the quality of life, in GP group, the general condition KPS score increased in 3 cases, and kept stable in 14 cases ; whereas in G group there were 11 and 24 cases respectively, with no significant difference between two groups （P 〉0.05） ）. In GP group, weight was increased in 7 cases, and stable in 13 cases; whereas in G group there were 15 and 21 cases respectively, with significant difference between two groups （ P 〈 0. 05 ）. The main side effects were myelosuppression. The WHO grade Ⅲ/Ⅳ leucopenia occurrence rates were 11.1% and 7.5% in the two groups and the grade Ⅲ/Ⅳthrombocytopenia occurrence rates were 2.7% and 5.0% respectively in the GP and G group. No significant difference was observed（P 〉0.05）. The grade Ⅲ/Ⅳ vomiting and disgusting occurrence was 52.7% （19 cases） in the GP group, which was significant higher than that in the G group（ P 〈 0. 05 ）. The other adverse reactions were mild, which could be tolerated. Conclusion ： The curative effects by G and GP treatment for advanced NSCLC of the old age are similar, but the toxicity responses are more endurable with better quality of life in G group. So from the adverse reactions and tolerability, single-a
出处
《肿瘤预防与治疗》
2010年第2期125-128,共4页
Journal of Cancer Control And Treatment
关键词
吉西他滨
老年
非小细胞肺癌
化疗
Gemcitabine
Elderly
Non-Small Cell Lung Cancer
Chemotherapy
